Tags

Type your tag names separated by a space and hit enter

Efficacy of miltefosine for the treatment of American cutaneous leishmaniasis.
Am J Trop Med Hyg. 2010 Aug; 83(2):351-6.AJ

Abstract

Miltefosine is an oral agent used for cutaneous leishmaniasis treatment. An open-label, randomized, phase III clinical trial was carried out in the Colombian army population. Miltefosine, 50 mg capsule was taken orally three times per day for 28 days (N = 145) or meglumine antimoniate, 20 mg/kg body weight per day for 20 days by intramuscular injection (N = 143). The efficacy of miltefosine by protocol was 69.8% (85/122 patients) and 58.6% (85/145 patients) by intention to treat. For meglumine antimoniate, the efficacy by protocol was 85.1% (103/121 patients) and 72% (103/143 patients) by intention to treat. No association was found between drug efficacy and L. (V.) braziliensis or L. (V.) panamensis species of Leishmania responsible for infection. Adverse gastrointestinal events were associated with the use of miltefosine, the meglumine antimoniate treatment was associated with adverse effects on the skeletal musculature, fever, cephalea, and higher toxicity in kidney, liver, pancreas, and hematological system.

Authors+Show Affiliations

Universidad de Antioquia, Medellín, Colombia. idvelez@pecet-colombia.orgNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial, Phase III
Journal Article
Multicenter Study
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

20682881

Citation

Vélez, Iván, et al. "Efficacy of Miltefosine for the Treatment of American Cutaneous Leishmaniasis." The American Journal of Tropical Medicine and Hygiene, vol. 83, no. 2, 2010, pp. 351-6.
Vélez I, López L, Sánchez X, et al. Efficacy of miltefosine for the treatment of American cutaneous leishmaniasis. Am J Trop Med Hyg. 2010;83(2):351-6.
Vélez, I., López, L., Sánchez, X., Mestra, L., Rojas, C., & Rodríguez, E. (2010). Efficacy of miltefosine for the treatment of American cutaneous leishmaniasis. The American Journal of Tropical Medicine and Hygiene, 83(2), 351-6. https://doi.org/10.4269/ajtmh.2010.10-0060
Vélez I, et al. Efficacy of Miltefosine for the Treatment of American Cutaneous Leishmaniasis. Am J Trop Med Hyg. 2010;83(2):351-6. PubMed PMID: 20682881.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Efficacy of miltefosine for the treatment of American cutaneous leishmaniasis. AU - Vélez,Iván, AU - López,Liliana, AU - Sánchez,Ximena, AU - Mestra,Laureano, AU - Rojas,Carlos, AU - Rodríguez,Erwin, PY - 2010/8/5/entrez PY - 2010/8/5/pubmed PY - 2010/9/9/medline SP - 351 EP - 6 JF - The American journal of tropical medicine and hygiene JO - Am J Trop Med Hyg VL - 83 IS - 2 N2 - Miltefosine is an oral agent used for cutaneous leishmaniasis treatment. An open-label, randomized, phase III clinical trial was carried out in the Colombian army population. Miltefosine, 50 mg capsule was taken orally three times per day for 28 days (N = 145) or meglumine antimoniate, 20 mg/kg body weight per day for 20 days by intramuscular injection (N = 143). The efficacy of miltefosine by protocol was 69.8% (85/122 patients) and 58.6% (85/145 patients) by intention to treat. For meglumine antimoniate, the efficacy by protocol was 85.1% (103/121 patients) and 72% (103/143 patients) by intention to treat. No association was found between drug efficacy and L. (V.) braziliensis or L. (V.) panamensis species of Leishmania responsible for infection. Adverse gastrointestinal events were associated with the use of miltefosine, the meglumine antimoniate treatment was associated with adverse effects on the skeletal musculature, fever, cephalea, and higher toxicity in kidney, liver, pancreas, and hematological system. SN - 1476-1645 UR - https://www.unboundmedicine.com/medline/citation/20682881/Efficacy_of_miltefosine_for_the_treatment_of_American_cutaneous_leishmaniasis_ L2 - https://ajtmh.org/doi/10.4269/ajtmh.2010.10-0060 DB - PRIME DP - Unbound Medicine ER -